Drugs / ACDN-01
ACDN-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06467344 | Jun 2024 → Aug 2030 expected | Stargardt disease, cone-rod dystrophy, macular degeneration, early-onset | Ascidian Therapeutics, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACDN-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06467344 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “ACDN-01 is an AAV-based vector” NCT06467344 ↗ |
| Route | Other | “via subretinal injection” NCT06467344 ↗ |
| Target | ABCA4 | “an ABCA4 RNA exon editor” NCT06467344 ↗ |